Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Conditions: Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors Interventions: Drug: zanzalintinib; Drug: AB521; Biological: Nivolumab Sponsors: Exelixis; Arcus Biosciences, Inc. Recruiting

https://clinicaltrials.gov/study/NCT06191796

Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials